Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03027102
Recruitment Status : Recruiting
First Posted : January 20, 2017
Last Update Posted : December 12, 2019
Sponsor:
Collaborator:
Ozmosis Research Inc.
Information provided by (Responsible Party):
University Health Network, Toronto

Brief Summary:
This study aims to determine the safety and toxicity of incremental doses of Double Negative T (DNT) cells in human subjects with high risk acute myeloid leukemia (AML). DNT cells are mature T lymphocytes that comprise ~1% of white blood cells in humans. Injection of DNTs from healthy donors has been demonstrated to be effective against AML cells. DNT cells will be collected from healthy volunteers and injected into patients.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Biological: DNT cells Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Allogeneic Double Negative T Cells (DNT-UHN-1) in Patients With High Risk Acute Myeloid Leukemia
Actual Study Start Date : August 15, 2017
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : September 2021


Arm Intervention/treatment
Experimental: Patient Arm
Patients will receive DNT cells from healthy donors.
Biological: DNT cells
DNT cells will be expanded (increased in numbers) in the laboratory, in order to enhance their tumour destroying potential before infusion into AML patients.

No Intervention: Donor Arm
Healthy volunteer donors will donate blood.



Primary Outcome Measures :
  1. Number of patients with adverse events and abnormal laboratory studies. [ Time Frame: 2 years ]
    Patients will be assessed for adverse events based upon, but not limited to, monitoring of vital signs and prescribed laboratory studies. Adverse events (AE) will use the descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE). This study will utilize the CTCAE Version 4.03 for adverse event reporting.


Secondary Outcome Measures :
  1. Number of cells with disease specific mutations per patient [ Time Frame: 2 years ]
    Quantitive real time polymerase chain reaction (PCR) analysis for disease specific mutations will be performed on the bone marrow aspirate.

  2. Leukemia load [ Time Frame: 2 years ]
    Peripheral blood will be obtained after DNT cell infusion to monitor leukemia load and residual disease by determining the frequency of leukemic cell markers on cells using flow cytometry.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Patient Inclusion Criteria:

  1. Patients with AML who are 18 years of age or older.
  2. Viably frozen cells from the time of diagnosis or relapse are available for sensitivity testing to DNT cells.
  3. Patients have given informed consent.
  4. Patients in remission following FLAG-Ida induction therapy who are receiving consolidation treatment.
  5. Creatinine < 1.5 x ULN within 7 days prior to day 1 of study treatment.
  6. AST, ALP, bilirubin < 1.5x ULN within 7 days prior to day 1 of study treatment.
  7. Female patients of childbearing potential should be willing to use 2 methods of birth control (Refer to section 9.2.15 or be surgically sterile, or abstain from heterosexual activity for the course of the study from day 1 until 1 months following chemotherapy. Patients of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 2 years.

    Male patients should use condoms or abstain from sex from the time of beginning chemotherapy to 1 month after the chemotherapy.

  8. Patients must be able to comply with study procedures, at the minimum, until all DNT-UHN-1 cells are out of their system.

Patient Exclusion Criteria:

  1. ECOG performance status <2.
  2. Patients with a known persistent infection.
  3. Patients with known active CNS disease.
  4. Life expectancy < 3 months.
  5. Patients should be off Cox2 inhibitors and corticosteroids for at least 3 days prior to and 7 days after infusion of DNT cells.
  6. Patients who are HIV positive.
  7. Patients for whom healthy donor DNT kill <10% of patient's blast cells.

Donor Inclusion Criteria:

  1. Has given written informed consent.
  2. Is 18 years of age or older.
  3. No known prior blood product transfusion or surgery.
  4. Blood electrolytes (Sodium, Potassium, Chloride, Bicarbonate, Magnesium, Phosphate, Calcium) within normal ranges.
  5. Normal complete blood counts.
  6. Normal liver and kidney function (Bilirubin, AST, ALT, ALP, LDH, plasma albumin, creatinine).
  7. Negative for transfusion transmissible illnesses (CMV, HIV I/II, HTLV I/II, Hepatitis B Surface Antigen, Hepatitis B Surface Antibody, Hepatitis B Core Antibody, Hepatitis C Antibody) within 30 days of blood collection for DNT cell expansion for patient infusion.
  8. Negative for evidence of exposure to West Nile Virus, Syphilis within 30 days of blood collection for DNT cell expansion for patient infusion.
  9. DNT cell expansion yield is >108 per mL blood using the standard protocol. Expanded DNT cells show ≥20% cytotoxicity to at least 3 AML cell lines (MV4-11 AML3, and U937).
  10. The donor who meet all donor inclusion/exclusion criteria, whose DNT cells show the most potent killing (minimum >10% killing) of AML patient's blast cells (blast cells frozen at time of diagnosis or relapse) will be approached for participation in this study.

Donor Exclusion Criteria:

  1. With a history of high risk behavior including, but not limited to, a history of piercing (except ear lobes), tattoos or other body modification.
  2. Has serious illnesses such as cardiovascular disease & cancer.
  3. Has sexually transmissible disease.
  4. Has history of intravenous drug use.
  5. Persons who received any vaccinations in past 3 months prior to enrolment into this study.
  6. Persons who travel outside the U.S. and Canada in the past 3 years prior to enrolment into this study, to areas that are considered endemic for malaria.
  7. Persons who have received blood components or other human tissues in the past 12 months prior to enrolment into this study (however this may be reduced to 6 months if nucleic acid testing (NAT) is used for the tests).
  8. Pregnant or lactating.
  9. Persons at risk of transmitting a hematological or immunological disease.
  10. Persons with transmissible genetic diseases in the family.
  11. On prescription medication.
  12. Persons with prion-related disease.
  13. Persons with a neurological disease of an unestablished etiology.
  14. Persons with active encephalitis or meningitis of infectious or unknown etiology.
  15. Persons with rabies or persons who, within the past 6 months, were bitten by an animal and treated as if the animal was rabid.
  16. Persons with a family history of Creutzfeldt-Jakob disease.
  17. Persons who have received human-derived pituitary growth hormone or dura mata.
  18. Persons who have known or suspected sepsis at the time of donation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03027102


Contacts
Layout table for location contacts
Contact: Mark Minden, MD 416-946-2015 mark.minden@uhn.ca

Locations
Layout table for location information
Canada, Ontario
Princess Margaret Cancer Centre Recruiting
Toronto, Ontario, Canada, M5G2M9
Contact: Mark Minden         
Sponsors and Collaborators
University Health Network, Toronto
Ozmosis Research Inc.
Layout table for additonal information
Responsible Party: University Health Network, Toronto
ClinicalTrials.gov Identifier: NCT03027102    
Other Study ID Numbers: OZM-079
First Posted: January 20, 2017    Key Record Dates
Last Update Posted: December 12, 2019
Last Verified: December 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by University Health Network, Toronto:
allogenic double negative T cells
DNT cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms